Does EBV trigger multiple sclerosis and drive its progression?
Evelyn Peelen, Head of Research, Andreas Muehler, Chief Medical Officer, and Hella Kohlhof, Chief Scientific Officer at Immunic Therapeutics discuss the unmet need for MS treatments that combine neuroprotective, anti-inflammatory, and antiviral properties.
For a long time, multiple sclerosis (MS) has been viewed as a disease driven solely by peripheral immune activation—yet most current therapies target only these immune responses. However, MS also involves chronic inflammation and progressive neurodegeneration within the central nervous system (CNS). Meanwhile, growing evidence implicates Epstein-Barr virus (EBV)—a lifelong resident in B lymphocytes—not just as a trigger, but as a potential driver of the disease. If EBV is part of the engine behind MS, should antiviral therapies play a bigger role in its treatment?

MS pathophysiology and the role of EBV
MS is a debilitating neurological autoimmune disease with four main subtypes: clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS). While CIS is characterised by clinically silent magnetic resonance imaging (MRI)-visible lesions, RRMS, affecting around 85% of patients1 , presents with bouts of symptoms, called relapses, followed by complete or partial recovery. Over time, approximately 62% of RRMS patients transition into SPMS2,3,4 with (active SPMS) or without (non-active SPMS) MRI lesions and/or relapses present. PPMS occurs in ~15% of MS patients1 and progresses steadily from onset.
While relapses are a key symptom of MS, recent studies show that progression independent of relapse activity (PIRA) is a major driver of long-term disability, more so than relapse-associated worsening (RAW)5. This highlights the disease’s complexity, with PIRA characterising a more smoldering, chronic inflammatory process present to varying degrees across all MS types.
A hallmark of MS pathology is immune cell infiltration into the CNS. Mainly pathogenic T and B lymphocytes cause inflammation, demyelination, and neurodegeneration6. This drives inflammation mainly in relapsing MS, while progressive MS is marked by more compartmentalised, chronic inflammation, such as meningeal immune cell aggregates and microglial activation7. Genetic predisposition and environmental factors, including EBV infection, vitamin D deficiency, and smoking, also seem to contribute to disease onset and progression.
EBV: A key trigger in MS?
EBV infects about 95% of adults8. Usually acquired through saliva, it establishes latency and persists lifelong in B lymphocytes after initial replication in epithelial cells in the throat and mouth9. Though often controlled by the immune system, reactivation can occur due to a weakened immune system, B lymphocyte activation, stress, infections or genetic predispositions10,11,12,13. Notably, EBV reactivation has been linked to post-Covid syndrome (PCS), where fatigue is a major symptom—which is also true for MS14.
Strong evidence linking EBV to MS comes from Bjornevik15, who studied over 10 million US military personnel and found that EBV infection preceded MS onset in nearly all cases. Adult EBV infection increased MS risk 32-fold, suggesting EBV is a prerequisite for the disease. Other viral infections did not appear to impact the likelihood of developing MS.
EBV and its impact on MS: A catalyst in MS progression?
EBV-infected B lymphocytes may play a central role in MS. They can infiltrate the CNS, evade immune clearance, and promote inflammation through secretion of pro-inflammatory factors and activation of CNS resident glial cells16,17,18. Several studies indicate impaired EBV-specific immunity in MS patients, suggesting a dysfunctional immune response that allows persistent viral infection 19,20,21. Genetic factors may also influence this interaction, as HLA-DRB1*1501 risk allele are associated with elevated anti-EBV antibody levels, hinting at a link between genetics, EBV immune responses, and MS risk22. Additionally, oligoclonal bands—an MS characteristic—contain antibodies that appear to recognise EBV and/or neural antigens, consistent with molecular mimicry between viral and CNS proteins. This mechanism may drive both B and T cell autoreactive responses23,24,25.
While EBV reactivation has been suggested to contribute to relapses as a possible trigger, both dormant and active EBV-infected B lymphocytes have been found in MS brain parenchyma and meninges26,27,28. This presence may play a role in sustaining low-grade inflammation that potentially drives the gradual neurodegeneration seen in PIRA. Thus, EBV could potentially contribute to both acute inflammatory episodes underlying relapses and to chronic smoldering inflammation linked to PIRA, positioning the virus as a key catalyst throughout the clinical course of MS.
Potential for antiviral approaches
Current MS treatments include steroids for relapses and disease-modifying therapies (DMTs) that reduce relapses but often fail to prevent disability progression linked to PIRA5. This gap is especially evident in PPMS and non-active SPMS, where effective treatments are scarce.
B cell-depleting therapies offer some benefit in PPMS, possibly by reducing EBV reservoirs. Supporting this, ocrelizumab-treated patients show decreased EBV-specific immune responses28,29. Fingolimod data further link EBV to MS, with reduced EBNA-1 IgG antibodies in more patients with RAW versus PIRA30.
Given EBV’s role, additional direct targeting of the virus may improve outcomes. While vaccination is challenging, therapies suppressing EBV reactivation or modulating EBV immune responses/reservoir are promising. These include:
- BTK inhibitors (such as tolebrutinib, evobrutinib, orelabrutinib, fenebrutinib) targeting B cells and microglia
- CD19-targeted chimeric antigen receptor (CAR) T cell therapy
- Mesenchymal stem cells with immunomodulatory and neuro-regenerative potential
- Vidofludimus calcium, combining neuroprotective (Nurr1 activation) and anti-inflammatory/antiviral effects (DHODH inhibition)
Conclusion
Emerging evidence underlines EBV’s significant role in MS initiation and progression. Its involvement offers a new lens to better understand the disease and motivates the pursuit of antiviral therapies. Current MS treatments primarily address inflammation and relapses but are insufficient to stop PIRA-driven disability progression. Therefore, expanding therapeutic strategies to address PIRA—potentially by targeting EBV-infected B cells and modulating chronic immune responses—are urgently needed. Validating EBV’s contribution to MS through clinical trials and mechanistic studies will be crucial for future breakthroughs in treatment.
About the authors
Evelyn Peelen, PhD, joined Immunic Therapeutics in 2019. As Head of Research, she executes and oversees research programmes and outcomes in alignment with the company’s strategic vision. Before, she worked in academia, first as a PhD student at the University of Maastricht, The Netherlands, then as a postdoctoral fellow at the Biomedical Research Institute, Hasselt University, Belgium, and lastly as a postdoctoral fellow at the Research Center of the Centre Hospitalier de L’Université de Montréal (CHUM), Canada.
Andreas Muehler, MD, MBA, joined Immunic Therapeutics in August 2016 as Chief Medical Officer. From 2009 until joining Immunic, Dr Muehler was an independent medical consultant, serving in key interim leadership roles at a number of pharmaceutical and medical device companies.
Hella Kohlhof, PhD, joined Immunic Therapeutics in January 2017 as Chief Scientific Officer. In 2008, Dr Kohlhof joined 4SC AG and held several positions, including Director of Development Projects, where she was responsible for the entire product development pipeline of 4SC.
References
1: Klineova S, Lublin FD. Clinical Course of Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):a028928. doi: 10.1101/cshperspect.a028928. PMID: 29358317; PMCID: PMC6120692.
2: Tutuncu M, Tang J, Zeid NA, Kale N, Crusan DJ, Atkinson EJ, Siva A, Pittock SJ, Pirko I, Keegan BM, Lucchinetti CF, Noseworthy JH, Rodriguez M, Weinshenker BG, Kantarci OH. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler. 2013 Feb;19(2):188-98. doi: 10.1177/1352458512451510. Epub 2012 Jun 26. PMID: 22736750; PMCID: PMC4029334.
3: Rice CM, Cottrell D, Wilkins A, et alPrimary progressive multiple sclerosis: progress and challengesJournal of Neurology, Neurosurgery & Psychiatry 2013;84:1100-1106.
4: Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol. 2006 Apr;5(4):343-54. doi: 10.1016/S1474-4422(06)70410-0. PMID: 16545751.
5: Lublin FD, Häring DA, Ganjgahi H, Ocampo A, Hatami F, Čuklina J, Aarden P, Dahlke F, Arnold DL, Wiendl H, Chitnis T, Nichols TE, Kieseier BC, Bermel RA. How patients with multiple sclerosis acquire disability. Brain. 2022 Sep 14;145(9):3147-3161. doi: 10.1093/brain/awac016. PMID: 35104840; PMCID: PMC9536294.
6: Bierhansl L, Hartung HP, Aktas O, Ruck T, Roden M, Meuth SG. Thinking outside the box: non-canonical targets in multiple sclerosis. Nat Rev Drug Discov. 2022 Aug;21(8):578-600. doi: 10.1038/s41573-022-00477-5. Epub 2022 Jun 6. PMID: 35668103; PMCID: PMC9169033.
7: Yong HYF, Yong VW. Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis. Nat Rev Neurol. 2022 Jan;18(1):40-55. doi: 10.1038/s41582-021-00581-x. Epub 2021 Nov 3. PMID: 34732831.
8: Kuri A, Jacobs BM, Vickaryous N, Pakpoor J, Middeldorp J, Giovannoni G, Dobson R. Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom. BMC Public Health. 2020 Jun 12;20(1):912. doi: 10.1186/s12889-020-09049-x. PMID: 32532296; PMCID: PMC7291753.
9: Hutt-Fletcher LM. Epstein-Barr virus replicating in epithelial cells. Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16242-3. doi: 10.1073/pnas.1418974111. Epub 2014 Nov 10. PMID: 25385596; PMCID: PMC4246291.
10: Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA. Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med. 1999 Aug 16;190(4):567-76. doi: 10.1084/jem.190.4.567. PMID: 10449527; PMCID: PMC2195601.
11: Kerr JR. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors. J Clin Pathol. 2019 Oct;72(10):651-658. doi: 10.1136/jclinpath-2019-205822. Epub 2019 Jul 17. PMID: 31315893.
12: Omkar Indari, Subhrojyoti Ghosh, Adhiraj Singh Bal, Ajay James, Mehek Garg, Amit Mishra, Krishanpal Karmodiya, Hem Chandra Jha, Awakening the sleeping giant: Epstein–Barr virus reactivation by biological agents, Pathogens and Disease, Volume 82, 2024, ftae002, https://doi.org/10.1093/femspd/ftae002
13: Damania B, Kenney SC, Raab-Traub N. Epstein-Barr virus: Biology and clinical disease. Cell. 2022 Sep 29;185(20):3652-3670. doi: 10.1016/j.cell.2022.08.026. Epub 2022 Sep 15. PMID: 36113467; PMCID: PMC9529843.
14: Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens. 2021 Jun 17;10(6):763. doi: 10.3390/pathogens10060763. PMID: 34204243; PMCID: PMC8233978.
15: Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, Elledge SJ, Niebuhr DW, Scher AI, Munger KL, Ascherio A. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022 Jan 21;375(6578):296-301. doi: 10.1126/science.abj8222. Epub 2022 Jan 13. PMID: 35025605.
16: Rousseau BA, Bhaduri-McIntosh S. Inflammation and Epstein-Barr Virus at the Crossroads of Multiple Sclerosis and Post-Acute Sequelae of COVID-19 Infection. Viruses. 2023 Apr 12;15(4):949. doi: 10.3390/v15040949. PMID: 37112929; PMCID: PMC10141000.
17: Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, Andreoni L, Trivedi P, Salvetti M, Faggioni A, Aloisi F. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007 Nov 26;204(12):2899-912. doi: 10.1084/jem.20071030. Epub 2007 Nov 5. PMID: 17984305; PMCID: PMC2118531.
18: Orr N, Steinman L. Epstein-Barr virus and the immune microenvironment in multiple sclerosis: Insights from high-dimensional brain tissue imaging. Proc Natl Acad Sci U S A. 2025 Mar 18;122(11):e2425670122. doi: 10.1073/pnas.2425670122. Epub 2025 Mar 10. PMID: 40063794; PMCID: PMC11929469.
19: Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, Ruggieri S, Gasperini C, Buttari F, Centonze D, Mechelli R, Salvetti M, Borsellino G, Aloisi F, Battistini L. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 2013;9(4):e1003220. doi: 10.1371/journal.ppat.1003220. Epub 2013 Apr 11. PMID: 23592979; PMCID: PMC3623710.
20: Vietzen H, Berger SM, Kühner LM, Furlano PL, Bsteh G, Berger T, Rommer P, Puchhammer-Stöckl E. Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis. Cell. 2023 Dec 21;186(26):5705-5718.e13. doi: 10.1016/j.cell.2023.11.015. Epub 2023 Dec 12. PMID: 38091993.
21: Pender MP, Csurhes PA, Burrows JM, Burrows SR. Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis. Clin Transl Immunology. 2017 Jan 20;6(1):e126. doi: 10.1038/cti.2016.87. Erratum in: Clin Transl Immunology. 2017 Jun 16;6(6):e147. doi: 10.1038/cti.2017.25. PMID: 28197337; PMCID: PMC5292561.
22: De Jager PL, Simon KC, Munger KL, Rioux JD, Hafler DA, Ascherio A. Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology. 2008 Mar 25;70(13 Pt 2):1113-8. doi: 10.1212/01.wnl.0000294325.63006.f8. Epub 2008 Feb 13. PMID: 18272866.
23: Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, Fernandes RA, Gomez AM, Nadj GS, Bartley CM, Schubert RD, Hawes IA, Vazquez SE, Iyer M, Zuchero JB, Teegen B, Dunn JE, Lock CB, Kipp LB, Cotham VC, Ueberheide BM, Aftab BT, Anderson MS, DeRisi JL, Wilson MR, Bashford-Rogers RJM, Platten M, Garcia KC, Steinman L, Robinson WH. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022 Mar;603(7900):321-327. doi: 10.1038/s41586-022-04432-7. Epub 2022 Jan 24. PMID: 35073561; PMCID: PMC9382663.
24: Münz C. Altered EBV specific immune control in multiple sclerosis. J Neuroimmunol. 2024 May 15;390:578343. doi: 10.1016/j.jneuroim.2024.578343. Epub 2024 Apr 5. PMID: 38615370.
25: Serafini B, Rosicarelli B, Veroni C, Aloisi F. Tissue-resident memory T cells in the multiple sclerosis brain and their relationship to Epstein-Barr virus infected B cells. J Neuroimmunol. 2023 Mar 15;376:578036. doi: 10.1016/j.jneuroim.2023.578036. Epub 2023 Jan 26. PMID: 36753806.
26: Angelini MM, Akhlaghpour M, Neuman BW, Buchmeier MJ. Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles. mBio. 2013 Aug 13;4(4):e00524-13. doi: 10.1128/mBio.00524-13. PMID: 23943763; PMCID: PMC3747587.
27: Schneider-Hohendorf T, Gerdes LA, Pignolet B, Gittelman R, Ostkamp P, Rubelt F, Raposo C, Tackenberg B, Riepenhausen M, Janoschka C, Wünsch C, Bucciarelli F, Flierl-Hecht A, Beltrán E, Kümpfel T, Anslinger K, Gross CC, Chapman H, Kaplan I, Brassat D, Wekerle H, Kerschensteiner M, Klotz L, Lünemann JD, Hohlfeld R, Liblau R, Wiendl H, Schwab N. Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis. J Exp Med. 2022 Nov 7;219(11):e20220650. doi: 10.1084/jem.20220650. Epub 2022 Sep 1. Erratum in: J Exp Med. 2022 Nov 7;219(11):e2022065010252022c. doi: 10.1084/jem.2022065010252022c. PMID: 36048016; PMCID: PMC9437111.
28: Tilman Schneider-Hohendorf, Christian Wünsch, Simon Falk, Catarina Raposo, Florian Rubelt, Hamid Mirebrahim, Hosseinali Asgharian, Ulrich Schlecht, Daniel Mattox, Wenyu Zhou, Eva Dawin, Marc Pawlitzki, Sarah Lauks, Sven Jarius, Brigitte Wildemann, Joachim Havla, Tania Kümpfel, Miriam-Carolina Schrot, Marius Ringelstein, Markus Kraemer, Carolin Schwake, Thomas Schmitter, Ilya Ayzenberg, Katinka Fischer, Sven G Meuth, Orhan Aktas, Martin W Hümmert, Julian R Kretschmer, Corinna Trebst, Ilka Kleffner, Jennifer Massey, Paolo A Muraro, Haiyin Chen-Harris, Catharina C Gross, Luisa Klotz, Heinz Wiendl, Nicholas Schwab, Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation, Brain, Volume 148, Issue 3, March 2025, Pages 933–940, https://doi.org/10.1093/brain/awae244
29: Abbadessa G, Lepore MT, Bruzzaniti S, Piemonte E, Miele G, Signoriello E, Perna F, De Falco C, Lus G, Matarese G, Bonavita S, Galgani M. Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8+ T-Cell Proliferation in Patients With Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2024 Jul;11(4):e200250. doi: 10.1212/NXI.0000000000200250. Epub 2024 Apr 25. PMID: 38662990; PMCID: PMC11087045.
30: Dominguez-Mozo MI, Galán V, Ramió-Torrentà L, Quiroga A, Quintana E, Villar LM, Costa-Frossard L, Fernández-Velasco JI, Villarrubia N, Garcia-Martinez MA, Arroyo R, Alvarez-Lafuente R. A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression. Front Immunol. 2024 Jun 7;15:1384411. doi: 10.3389/fimmu.2024.1384411. PMID: 38911861; PMCID: PMC11190074.
